WO2009099959A3 - Tumor cell expression of neuropilin as a target for cancer therapy - Google Patents

Tumor cell expression of neuropilin as a target for cancer therapy Download PDF

Info

Publication number
WO2009099959A3
WO2009099959A3 PCT/US2009/032689 US2009032689W WO2009099959A3 WO 2009099959 A3 WO2009099959 A3 WO 2009099959A3 US 2009032689 W US2009032689 W US 2009032689W WO 2009099959 A3 WO2009099959 A3 WO 2009099959A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropilin
target
nucleic acid
tumor cell
cancer therapy
Prior art date
Application number
PCT/US2009/032689
Other languages
French (fr)
Other versions
WO2009099959A2 (en
Inventor
Lee M. Ellis
Michael J. Gray
Anil K. Sood
Gabriel Lopez-Berestein
Original Assignee
The Board Of Regents Of Teh University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of Teh University Of Texas System filed Critical The Board Of Regents Of Teh University Of Texas System
Publication of WO2009099959A2 publication Critical patent/WO2009099959A2/en
Publication of WO2009099959A3 publication Critical patent/WO2009099959A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compositions that include a nucleic acid component that include a nucleic acid that inhibits the expression of a gene that encodes a neuropilin, and a lipid component that includes one or more neutral phospholipids. Also disclosed are compositions that include a nucleic acid component that includes a nucleic acid that inhibits the expression of a gene that encodes neuropilin-2 (NRP-2). Also disclosed are methods of treating a subject with cancer that involve administering to the subject a pharmaceutically effective amount of a composition of the present invention.
PCT/US2009/032689 2008-01-31 2009-01-30 Tumor cell expression of neuropilin as a target for cancer therapy WO2009099959A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2521308P 2008-01-31 2008-01-31
US61/025,213 2008-01-31

Publications (2)

Publication Number Publication Date
WO2009099959A2 WO2009099959A2 (en) 2009-08-13
WO2009099959A3 true WO2009099959A3 (en) 2009-10-22

Family

ID=40952642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/032689 WO2009099959A2 (en) 2008-01-31 2009-01-30 Tumor cell expression of neuropilin as a target for cancer therapy

Country Status (1)

Country Link
WO (1) WO2009099959A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522341A1 (en) 2011-05-13 2012-11-14 Tragex Pharma Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
EP3677310A1 (en) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
EP2823816A1 (en) 2013-07-09 2015-01-14 Tragex Pharma Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases
CN108196071A (en) * 2018-02-09 2018-06-22 上海市第十人民医院 liver cancer serum marker NRP1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ELLIS, L. M. ET AL.: "The Role ofNeuropilins in Cancer", MOL. CANCER. THER., vol. 5, no. 5, May 2006 (2006-05-01), pages 1099 - 1107 *
FAVIER, B. ET AL.: "Neuropilin-2 Interacts with VEGFR-2 and VEGFR-3 and Promotes Human Endothelial Cell Survival and Migration", BLOOD, vol. 108, no. 4, 15 August 2006 (2006-08-15), pages 1243 - 1250 *
GRAY, M. J. ET AL.: "Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver", J. NAT'L CANCER INST., vol. 100, no. 2, 16 January 2008 (2008-01-16), pages 109 - 120 *
HALDER, J. ET AL.: "Focal Adhesion Kinase Targeting Using in vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy", CLIN. CANCER RES., vol. 12, no. 16, August 2006 (2006-08-01), pages 4916 - 4924 *
LANDEN, C. N. ET AL.: "Intraperitoneal Delivery ofLiposomal siRNA for Therapy of Advanced Ovarian Cancer", CANCER BIOL. THER., vol. 5, no. 12, December 2006 (2006-12-01), pages 1708 - 1713 *
LANDEN, C. N. ET AL.: "Therapeutic EphA2 Gene Targeting in vivo Using Neutral Liposomal Small Interfering RNA Delivery", CANCER RES., vol. 65, no. 15, August 2005 (2005-08-01), pages 6910 - 6918 *

Also Published As

Publication number Publication date
WO2009099959A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2011076807A3 (en) Lipids, lipid compositions, and methods of using them
MX2010004244A (en) Organic compounds.
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2008097640A8 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
WO2009087225A3 (en) Pyrrolopyrimidines and pyrrolopyridines
BRPI0915142A8 (en) POLYPEPTIDES, NUCLEIC ACID AND USES THEREOF
WO2009151598A8 (en) Diazacarbazoles and methods of use
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2008105852A3 (en) Mucoadhesive nanoparticles for cancer treatment
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2010048144A3 (en) Imaging and radiotherapy methods
NO20055209L (en) Peptabody for cancer treatment
WO2009077741A3 (en) 3-substituted-4-0x0-3, 4-dihydro-imidazo- [5, 1-d] [1,2,3,5] -tetrazine-8-carboxylic acid amides as anticancer agents
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
WO2009059201A3 (en) Id2 as a target in colorectal carcinoma
WO2009099959A3 (en) Tumor cell expression of neuropilin as a target for cancer therapy
WO2009070609A3 (en) Therapeutic targeting of il-6 using sirna in neutral liposomes
WO2008033891A3 (en) Azonafide derived tumor and cancer targeting compounds
ATE538105T1 (en) SUBSTITUTED TETRAZOLE COMPOUNDS AND THEIR USE
WO2010021750A3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2009126805A3 (en) Therapeutic tarageting of mmps in neutral liposomes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09707260

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09707260

Country of ref document: EP

Kind code of ref document: A2